43rd week of 2009 patent applcation highlights part 34 |
Patent application number | Title | Published |
20090263422 | INFLUENZA VACCINE - The present invention relates to monovalent influenza vaccine formulations and vaccination regimes for immunising against influenza disease, their use in medicine, in particular their use in augmenting immune responses to various antigens, and to methods of preparation. In particular, the invention relates to monovalent influenza immunogenic compositions comprising an influenza antigen or antigenic preparation thereof from an influenza virus strain being associated with a pandemic outbreak or having the potential to be associated with a pandemic outbreak, in combination with an oil-in-water emulsion adjuvant comprising a metabolisable oil, a sterol or a tocopherol such as alphatocopherol, and an emulsifying agent. | 2009-10-22 |
20090263423 | Enhancement of an Immune Response by Administration of a Cationic Lipid-DNA Complex (CLDC) - This invention relates to a method for vaccination which is effective for eliciting an enhanced antigen-specific immune response in a mammal, fish or bird. The method is particularly effective for protecting a mammal, fish or bird from a disease including cancer, a disease associated with allergic inflammation, or an infectious disease. Also disclosed are therapeutic compositions useful in such a method. | 2009-10-22 |
20090263424 | DEVELOPMENT OF MUTATIONS USEFUL FOR ATTENUATING DENGUE VIRUSES AND CHIMERIC DENGUE VIRUSES - A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines. | 2009-10-22 |
20090263425 | METHODS OF STIMULATING AN IMMUNE RESPONSE AGAINST PROSTATE SPECIFIC ANTIGEN - The invention provides a prostate specific antigen oligo-epitope peptide (PSA-OP) that is useful as an immunogen in the prevention or treatment of prostatic cancer and in the inhibition of prostatic cancer cells and in the establishment and characterization of PSA-specific cytotoxic T-cell lines. In particular, the invention provides methods for eliciting an immune response against PSA comprising administering (i) a priming inoculation of a first recombinant virus encoding PSA-OP and (ii) one or more boosting inoculations of a second recombinant virus encoding PSA-OP, wherein the first and second recombinant viruses are from a different genus. | 2009-10-22 |
20090263426 | METHODS FOR TREATING HEADACHE - A headache can be treated more effectively by co-administration of a botulinum toxin and a triptan drug to a patient and/or the effectiveness of a triptan medication can be increased. The botulinum toxin can be botulinum toxin type A and the botulinum toxin can be administered to or to the vicinity of where a patient experiences or is predisposed to experience pain or a headache. | 2009-10-22 |
20090263427 | Vaccines for mycoplasma bovis and methods of use - The invention of novel, effective vaccines against | 2009-10-22 |
20090263428 | ARTIFICIAL LYMPH NODE FOR TREATING CANCER - Provided is an artificial lymph node that is persistently effective in cancer treatment in vivo. | 2009-10-22 |
20090263429 | Method of Preparing a Hydrogel - A method of preparing a hydrogel comprises: (i) reacting a first molecule comprising a carboxylic acid group and second molecule comprising an amine group or an alcohol group with a hydrolase enzyme to form a product comprising an amide bond or ester bond, wherein the hydrolase enzyme would normally catalyse the production of an amine or an alcohol from an amide or an ester under physiological conditions; and (ii) maintaining the product comprising an amide or ester bond under conditions suitable to allow hydrogel formation. | 2009-10-22 |
20090263430 | Multilayer Silk Protein Films - The present invention is directed to a method of forming multilayer silk protein films and a multilayer film obtained therefrom. The invention is further directed to various materials, products and compositions containing said multilayer film and to the use of Said multilayer film in several applications. | 2009-10-22 |
20090263431 | POLYURETHANE FOAMS FOR WOUND MANAGEMENT - The invention relates to a process for producing polyurethane foams for wound management wherein a composition containing a polyurethane dispersion and specific coagulants is frothed and dried. | 2009-10-22 |
20090263432 | STABLE COMBINATIONS OF AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE - The present invention provides a pharmaceutical composition comprising benazepril and amlodipine wherein the benazepril and the amlodipine are in physical contact with one another, and methods for making the same. | 2009-10-22 |
20090263433 | COSMETIC COMPOSITION - Provided are a cosmetic composition which is an O | 2009-10-22 |
20090263434 | POWDER COMPOSED OF INORGANIC COMPOUND-LOADED POLYAMIDE POROUS PARTICLE - Powder composed of fine inorganic compound particles-deposited porous polyamide particles in which the inorganic compound particles are deposited on surfaces and in pores of the porous polyamide particles, the porous polyamide particle have a mean primary particle diameter in the range of 1 to 30 μm, the fine inorganic compound particles have a mean primary particle diameter in the range of 0.01 to 0.5 μm, and at least 80% of number of the fine inorganic compound particles contains no strong acidic component shows a high light-scattering property and gives no harmful effect to human body. | 2009-10-22 |
20090263435 | COMPOSITIONS AND METHODS FOR MINIMIZING AND/OR REDUCING THE APPEARANCE OF DEFECTS AROUND EYES - The invention relates to compositions comprising at least one xanthine compound, preferably further comprising at least one agent which acts on capillary circulation and/or at least one natural moisturizing agent, which can be used to treat, or to reduce and/or minimize the appearance of, defects such as dark circles, bags and/or puffiness around eyes. | 2009-10-22 |
20090263436 | Material primarily for medical, long-term in vivo use, and method for the production thereof - The invention relates to a material that is used primarily for medical, long-term in vivo purposes, e.g. as a filling material in dentistry. The aim of the invention is to create a material primarily for medical, long-term in vivo use which does not have the disadvantages of materials used in prior art, does not release active substances, and endures after the material has been removed or when the shape thereof is modified. The aim is achieved by the fact that the material is made of polymers and filling agents which are embodied as polymer-coated, chemically modified particles that carry hydroxyl groups and are surrounded by a matrix of another polymer. The coating polymer develops an antimicrobial effect. | 2009-10-22 |
20090263437 | PESTICIDE COMPOSITIONS - The present invention provides a granular pesticide composition which is highly effective in controlling pests. In particular, the pesticide composition of the present invention is prepared by adsorbing an oil in water emulsion on inert granular particles. These compositions provide improved release of the pesticide. Methods of preparing the granular pesticide composition and methods of use thereof are disclosed. | 2009-10-22 |
20090263438 | INHIBITION AND DISPERSION OF BACTERIAL BIOFILMS WITH IMIDAZOLE-TRIAZOLE DERIVATIVES - Disclosure is provided for imidazole-triazole derivative compounds that prevent, remove and/or inhibit the formation of biofilms, compositions comprising these compounds, devices comprising these compounds, and methods of using the same. | 2009-10-22 |
20090263439 | Antimicrobial Preservative Free Wipe - A mild and gentle antimicrobial active wet wipe comprising a substrate and a lotion with a pH that ranges from 2.5 to 5.4 and contains no chemical preservatives. | 2009-10-22 |
20090263440 | DISPOSABLE CONTAINERS AND UTENSILS FOR SANITIZING - A disposable container and/or utensil including an uncoated portion and a coated portion. The coated portion includes antibacterial agents and covers a substantially larger external surface area of the disposable container than the uncoated portion. The coated container includes, but is not limited to, a cup, a cup sleeve, or a food container. | 2009-10-22 |
20090263441 | DRUG DEPOTS HAVING DIFFREENT RELEASE PROFILES FOR REDUCING, PREVENTING OR TREATING PAIN AND INFLAMMATION - Effective treatments of pain and/or inflammation are provided. Through the administration of an effective amount of at least analgesic and/or at least one anti-inflammatory agent at or near a target site, one can reduce, prevent or treat inflammation and pain. | 2009-10-22 |
20090263442 | Post Biopsy Cavity Treatment Implants and Methods - A post-biopsy cavity treatment implant includes a radiopaque element, a core portion and a shell portion. The core portion is coupled to the radiopaque element, and includes a first porous matrix defining a first controlled pore architecture. The shell portion is coupled to the core portion and includes a second porous matrix defining a second controlled pore architecture that is different from the first controlled pore architecture. | 2009-10-22 |
20090263443 | METHODS FOR TREATING POST-OPERATIVE EFFECTS SUCH AS SPASTICITY AND SHIVERING WITH CLONDINE - Effective treatments of spasticity and shivering that accompanies surgeries are provided. Through the administration of an effective amount of clonidine at or near a target site, one can relax muscle fibers. This administration of clonidine or a pharmaceutically acceptable salt thereof is particularly useful following the surgery. | 2009-10-22 |
20090263444 | Fluocinolone Formulations in a Biodegradable Polymer Carrier - Effective treatments of pain and inflammation are provided. Through the administration of an effective amount of fluocinolone at or near a target site, one can reduce, prevent or treat inflammation and pain and autoimmune disorders. In various embodiments, fluocinolone formulations may be provided within biodegradable polymers to reduce, prevent or treat sciatic pain and/or inflammation. In various embodiments, prevent transplant rejection for at least twenty-five days. In some embodiments, the pain relief can be for at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days. | 2009-10-22 |
20090263445 | MEDICAL DEVICES COMPRISING SPRAY DRIED MICROPARTICLES - An implantable or insertable medical device which includes (a) a tacky polymeric region and (b) spray dried microparticles, which are adhered to the tacky polymeric region. The present invention is further directed to methods of forming such medical devices, and methods of releasing a therapeutic agent within a patient using such medical devices. | 2009-10-22 |
20090263446 | METHOD OF MAKING LOAD BEARING HYDROGEL IMPLANTS - Implantable biomaterials, particularly hydrogel substrates with porous surfaces, and methods for enhancing the compatibility of biomaterials with living tissue, and for causing physical attachment between biomaterials and living tissues are provided. Also provided are implants suitable for load-bearing surfaces in hard tissue repair, replacement, or augmentation, and to methods of their use. One embodiment of the invention relates to an implantable spinal disc prosthesis. | 2009-10-22 |
20090263447 | Crosslinked hyaluronic acid and process for the preparation thereof - The present invention relates to a crosslinked hyaluronic acid that can be obtained according to a process comprising: (a) activation of a hyaluronic acid, (b) reaction of the activated hyaluronic acid with an oligopeptide- or polypeptide-based crosslinking agent, in a reaction medium adjusted to a pH of from 8 to 12, so as to obtain a crosslinked hyaluronic acid, (c) adjustment of the pH of the reaction medium to a value ranging from 5 to 7, and (d) precipitation of the crosslinked hyaluronic acid from an organic solvent. | 2009-10-22 |
20090263448 | Clonidine Formulation in a Polyorthoester Carrier - Effective treatments of acute pain for extended periods of time are provided. The treatments include the administration of one or more drug depots at or near a target site wherein the drug depots include an effective amount of clonidine formulated within a polyorthoester. By administration of one or more drug depots at or near the target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discongenic back pain and joint pain, as well as pain that is incidental to surgery. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days or at least one hundred and thirty-five days. | 2009-10-22 |
20090263449 | DELIVERY OF NUCLEIC ACID COMPLEXES FROM MATERIALS INCLUDING NEGATIVELY CHARGED GROUPS - Embodiments of the invention include devices and methods for the controlled elution of nucleic acid delivery complexes. In an embodiment, the invention includes a medical device including a substrate surface, a polymeric coating disposed on the surface, the polymeric coating coupled to the substrate surface through the reaction product of a photoreactive group; the polymeric coating comprising negatively charged species on the surface; and a plurality of nucleic acid delivery complexes disposed on the polymeric coating, the nucleic acid delivery complexes comprising a nucleic acid and a cationic carrier agent complexed to the nucleic acid. Other embodiments are included herein. | 2009-10-22 |
20090263450 | ALPHA ADRENERGIC RECEPTOR AGONISTS FOR TREATMENT OF INFLAMMATORY DISEASES - Effective treatments of pain and/or inflammation from tendonitis, carpal tunnel syndrome, tarsal tunnel syndrome, osteoarthritis, bursitis and/or an oral-facial disease are provided. Through the administration of an effective amount of at least one alpha adrenergic agonist at or near a target site, one can reduce, prevent or treat pain and/or inflammation from tendonitis, carpal tunnel syndrome, tarsal tunnel syndrome, osteoarthritis, bursitis and/or an oral-facial disease. | 2009-10-22 |
20090263451 | Anti-Inflammatory and/or Analgesic Agents for Treatment of Myofascial Pain - Effective treatments of myofascial pain and/or inflammation are provided. Through the administration of an effective amount of at least one anti-inflammatory agent and/or analgesic at or near a target site, one can reduce, prevent or treat myofascial pain and/or inflammation. | 2009-10-22 |
20090263452 | Drug-eluting intravascular prostheses and methods of use - The present invention provides intravascular prostheses and methods of production and use. An implantable device for treating a vascular disease or disorder includes an intravascular prosthesis containing an inhibitor of smooth muscle cell proliferation and a growth factor. The device can be coated with a biodegradable drug-eluting polymer that is impregnated with the inhibitor of smooth muscle cell proliferation and the growth factor. The device is useful for treating or preventing a vascular disease or disorder such as restenosis, by simultaneously inhibiting vessel blockage and enhancing recovery of the vessel wall following an intravascular intervention. | 2009-10-22 |
20090263453 | Methods and Compositions for Treating Pain Comprising a Statin - Methods and compositions are provided for reducing, treating or preventing pain and/or inflammation in a patient in need of such treatment, the methods and compositions comprising administering a therapeutically effective amount of a statin or pharmaceutically acceptable salt thereof to a target tissue site beneath the skin. | 2009-10-22 |
20090263454 | ALPHA AND BETA ADRENERGIC RECEPTOR AGONISTS FOR TREATMENT OF PAIN AND / OR INFLAMMATION - Effective treatments of pain and/or inflammation are provided. Through the administration of an effective amount of at least one alpha adrenergic agonist and at least one beta adrenergic agonist at or near a target site, one can reduce, prevent or treat pain and/or inflammation. | 2009-10-22 |
20090263455 | Dexamethasone Formulations in a Bioegradable Material - Effective treatments of acute pain for extended periods of time are provided. Through the administration of an effective amount of dexamethasone at or near a target site, one can relieve pain cause by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discongenic back pain and joint pain as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least twenty-five days. In some embodiments, the relief can be for at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days. | 2009-10-22 |
20090263456 | Methods and Compositions for Reducing Preventing and Treating Adhesives - Methods and compositions are provided for reducing, treating or preventing adhesions in a patient in need of such treatment, the methods and compositions comprising administering one or more biodegradable drug depots comprising a therapeutically effective amount of a glucocorticoid or pharmaceutically acceptable salt thereof to a target tissue site beneath the skin, wherein the drug depot releases an effective amount of the glucocorticoid or pharmaceutically acceptable salt thereof to prevent in-growth of scar tissue and formation or reformation of adhesions at or near the target tissue site while an injured tissue heals. | 2009-10-22 |
20090263457 | BLOCK COPOLYMER COMPRISING AT LEAST ONE POLYESTER BLOCK AND A POLY(ETHYLENE GLYCOL) BLOCK - The present invention provides a block copolymer for a coating on an implantable device for controlling release of drug and methods of making and using the same. | 2009-10-22 |
20090263458 | MATERIAL FOR SURGICAL USE IN TRAUMATOLOGY - The present invention relates to a material, structure, and method for surgical use in traumatology. More particularly, the present invention relates to a composite material, a temporary biocompatible support structure, and related methods of use of the same in aiding osteosynthesis during healing of a bone fracture. The material keeps its strength in a solid phase in vivo and, to aid removal upon healing, can be transformed into a substantially fluid phase, including, for example, a pulverized state, by the application of energy at a chosen time. | 2009-10-22 |
20090263459 | METHODS AND COMPOSITIONS FOR TREATING INTERVERTEBRAL DISC HERNIATIONS - Methods and compositions are provided for treating an intervertebral disc herniation by local administration of one or more biodegradable drug depots comprising a therapeutically effective amount of a glucocorticoid at or near the intervertebral disc herniation to reduce the size of the intervertebral disc herniation. | 2009-10-22 |
20090263460 | MEDICAL DEVICES AND METHODS INCLUDING POLYMERS HAVING BIOLOGICALLY ACTIVE AGENTS THEREIN - The implant design is a drug loaded polymer device, such as a rod, designed to control the release of a biologically active agent, such as clonidine or its derivatives, such as clonidine HCl for a prolonged period of time, such as 2 months, 3 months, 4 months, and even 4.5 months. The polymer is preferably a biodegradable polymer, such as poly(lactide-co-glycolide) or polylactic acid/polylactide. The challenge in using the HCl salt forms of drugs such as clonidine, is controlling the release of the highly water soluble drug for up to 4.5 months. It has been found that by controlling the particle size distribution of the drug powder, the drug distribution within the polymer matrix is more uniform and can be controlled. Therefore, the large aggregates, which cause rapid drug release can be eliminated. | 2009-10-22 |
20090263461 | ALPHA ADRENERGIC RECEPTOR AGONISTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE - Effective treatments of pain and/or inflammation from degenerative disc disease and/or facet joint are provided. Through the administration of an effective amount of at least one alpha adrenergic agonist at or near a degenerative disc and/or facet joint, one can reduce, prevent or treat pain and/or inflammation caused by the degenerative disc disease and/or facet joint. | 2009-10-22 |
20090263462 | Methods for Treating Conditions Such as Dystonia and Post-Stroke Spasticity with Clonidine - Effective treatments of dystonia and/or post-stroke spasticity for extended periods of time are provided. Through the administration of an effective amount of clonidine at or near a target site, one can relieve dystonia and/or post-stroke spasticity caused by diverse sources. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least five days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days. | 2009-10-22 |
20090263463 | ALPHA ADRENERGIC RECEPTOR AGONISTS FOR TREATMENT OF PAIN AND/OR INFLAMMATION - Effective treatments of pain and/or inflammation are provided. Through the administration of an effective amount of at least one alpha adrenergic agonist at or near a target site, one can reduce, prevent or treat pain and/or inflammation. | 2009-10-22 |
20090263464 | BLADDER RECONSTRUCTION - The invention is directed to methods and devices for the reconstruction, repair, augmentation or replacement of laminarily organized luminal organs or tissue structures in a patient in need of such treatment. The device comprises a biocompatible synthetic or natural polymeric matrix shaped to conform to at least a part of the luminal organ or tissue structure with a first cell population on or in a first area and a second cell population such as a smooth muscle cell population in a second area of the polymeric matrix. The method involves grafting the device to an area in a patient in need of treatment. The polymeric matrix comprises a biocompatible and biodegradable material. | 2009-10-22 |
20090263465 | Biopolymer-Bioengineered Cell Sheet Construct - A biopolymer-bioengineered human corneal endothelial cell (HCEC) sheet construct for reconstructing corneal endothelium in a patient is recited. The construct includes a biopolymer carrier which is bioresorable and deformable; and a bioengineered cell sheet containing a monolayer of interconnected HCECs with substantially uniform orientation. The bioengineered cell sheet is attached to a surface of the biopolymer carrier with apical surfaces of the HCECs facing said carrier. | 2009-10-22 |
20090263466 | HERBAL COMPOSITION FOR TREATMENT OF HYPERLIPIDEMIA AND THE INHIBITION OF MYOCARDIAL INFARCTION - A pharmaceutical or medicinal herbal composition and method of making the composition comprised of a mixture of the following herbal ingredients: | 2009-10-22 |
20090263467 | COMBINATION DRUG THERAPY USING ORALLY DISSOLVING FILM OR ORALLY DISINTEGRATING TABLET DOSAGE FORMS TO TREAT DRY MOUTH AILMENTS - A combination drug therapy can be administered to patients to treat xerostomia or dry mouth or Sjogren's syndrome in the form of orally dissolving film or orally disintegrating tablets. Some of the drugs could be synthetic origin and some drugs are obtained from natural sources. | 2009-10-22 |
20090263468 | METHODS AND COMPOSITIONS FOR WOUND HEALING - The present invention relates to methods and compositions for wound healing. In particular, the present invention relates to promoting and enhancing wound healing by utilizing cross-linker covalent modification molecules to attach and deliver wound active agents to a wound. In addition, the present invention provides methods and compositions utilizing oppositely charged polymers to form a polyelectrolyte layer on a wound surface. The invention further relates to incorporating wound active agents into a polyelectrolyte layer for delivery to a wound. | 2009-10-22 |
20090263469 | BIGUANIDE-CONTAINING LIPOSOMES - The present invention relates to biguanide-containing liposomes and antiseptic preparations based on biguanide-containing liposomes, where the liposomes are characterised in that they are essentially free of lipids with anionic head groups, to the preparation of biguanide-containing liposomes and of the antiseptic preparations, and to their possible uses and to the products arising from their use, in particular wound dressings. | 2009-10-22 |
20090263470 | Vaccine Compositions Comprising Virosomes and a Saponin Adjuvant - This invention provides virosome preparations from an enveloped virus, in particular from influenza virus, containing from said virus, and a saponin adjuvant. In particular the invention provides a virosome preparation from influenza virus an influenza antigen a QS21, optionally with a sterol. The invention also provides vaccine compositions containing said virosome preparations, methods of preparing said virosome preparations and vaccine containing them. | 2009-10-22 |
20090263471 | Controlled Release Pharmaceutical Composition of Venlafaxine Hydrochloride, and Process for Preparation Thereof - Herein is described a controlled release pharmaceutical composition of venlafaxine hydrochloride, an effective antidepressant, comprising an inert core; on which the active principle is uniformly layered, that in turn is coated with a layer comprising a hardening agent and a lipophilic agent; the process for the preparation of said pharmaceutical composition is also described. | 2009-10-22 |
20090263472 | ENDOTHELIN RECEPTOR ANTAGONIST DERIVATIVES - Endothelin receptor antagonist nitroderivatives of general formula (I): | 2009-10-22 |
20090263473 | Nanoliposome Using Esterified Lecithin And Method For Preparing The Same, And Composition For Preventing Or Treating Skin Diseases Comprising The Same - The present invention relates to a nanoliposome comprising a liposome membrane containing esterified lecithin, and one or more physiologically active ingredients included in inner space of the liposome membrane; a method for preparing the same; and a composition for preventing or treating skin diseases, comprising the same. The nanoliposome according to the present invention has long-term stability and uniformity, and so can be used to prepare a composition for skin having excellent moisturizing and penetrating properties, such as cosmetics, medicament for treating skin diseases, or the like. In particular, the present composition for preventing or treating skin diseases comprises epidermal growth factor included in the nanoliposome, thereby showing an excellent effect of stimulating skin-penetration and good pharmaceutical stability. Also, the esterified lecithin used in preparing liposome can provide effects of softening skin and stimulating skin-penetration, thereby enhancing the penetration of epidermal growth factor and natural extract into skin, as well as additional moisturizing effect which is advantageous in treating skin diseases. Further, since the present composition comprises nanoliposome prepared by containing esterified lecithin in liposome membrane, the conventional problems of heating and dispersing active ingredients at high temperature (70° C. or more), low stability and uniformity, or the like can be solved. | 2009-10-22 |
20090263474 | Methods for Treating Autoimmune Diseases in a Subject and In Vitro Diagnostic Assays - The invention provides a method for treating an autoimmune disease in a subject by administering an interferon antagonist and a Flt3 ligand (Flt3L) antagonist. The invention also provides compositions containing one or more interferon antagonists, and one or more Flt3L antagonists, an in vitro assay for determining a subject's risk for developing an autoimmune disease, and kits for use, inter alia, with the assay. | 2009-10-22 |
20090263475 | DEXLANSOPRAZOLE COMPOSITIONS - Premixes of dexlansoprazole with pharmaceutical excipients, processes for preparing premixes, pharmaceutical formulations containing the premixes, and their use in treatment of erosive esophagitis and heartburn associated with non-erosive gastroesophageal reflux disease. | 2009-10-22 |
20090263476 | Composition of Rapid Disintegrating Direct Compression Buccal Tablet - A composition of a rapidly disintegrating buccal dosage form containing a drug, at least one non-effervescent base such as an alkali metal or alkaline earth metal oxide or hydroxide, and a disintegrant. The base regulates the pH gradient to deliver the drug to the buccal, sublingual or oral mucosal membranes at a desired rate of absorption. The composition is micronized for uniform distribution, and the drug is converted from ionized form to unionized form, without the use of an effervescent agent. | 2009-10-22 |
20090263477 | SALTS OF FENOFIBRIC ACID AND PHARMACEUTICAL FORMULATIONS THEREOF - In one aspect, the present invention relates to a formulation in the form of molecular dispersion comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients. | 2009-10-22 |
20090263478 | CARVEDILOL FORMS, COMPOSITIONS, AND METHODS OF PREPARATION THEREOF - Disclosed are amorphous carvedilol salt forms, controlled-release carvedilol compositions, and methods of preparing the forms and compositions. | 2009-10-22 |
20090263479 | FORMULATIONS FOR POORLY PERMEABLE ACTIVE PHARMACEUTICAL INGREDIENTS - The present invention relates to a pharmaceutical oral dosage form containing a poorly permeable active pharmaceutical ingredient and at least one permeability improving substance, wherein the permeability improving substance is thermostably embedded in a water-soluble matrix of a water soluble carrier, and to thermostable formulations which can be used to improve bioavailability. | 2009-10-22 |
20090263480 | TASTE-MASKED PHARMACEUTICAL COMPOSITIONS PREPARED BY COACERVATION - There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more taste-masked active pharmaceutical ingredients, rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients wherein the ODT disintegrates rapidly with saliva in the buccal cavity forming a smooth, easy-to-swallow suspension. Furthermore, the microparticles (crystals, granules, beads or pellets containing one or more actives) with a taste-masking membrane applied by a modified solvent coacervation process comprising a water-insoluble polymer and at least one gastrosoluble inorganic or organic pore-former, exhibit a pleasant taste when placed in the oral cavity and provide rapid, substantially-complete release of the dose on entry into the stomach. | 2009-10-22 |
20090263481 | LEVETIRACETAM FORMULATIONS - Pharmaceutical formulations comprising levetiracetam and having an inner solid phase and outer continuous phase, wherein one or both of the phases comprise at least one hydrophobic material, lipophilic material, or combination thereof. | 2009-10-22 |
20090263482 | Treatment of inflammatory bowel disease with 6-mercaptopurine - Methods of administering a delayed release 6-mercaptopurine pharmaceutical composition to patients suffering from inflammatory bowel disease which provide for release of the 6-mercaptopurine after passage of the pharmaceutical composition through the stomach are disclosed. The methods result in significant clinical improvement despite leading to very little systemic absorption of 6-mercaptopurine and also result in very few undesirable side effects. | 2009-10-22 |
20090263483 | NANOPARTICLE FORMULATIONS AND USES THEREOF - The present invention provides compositions comprising nanoparticles comprising: 1) a drug, such as a hydrophobic drug derivative; and 2) a carrier protein. Also provided are methods of treating diseases (such as cancer) using the compositions, as well as kits and unit dosages. | 2009-10-22 |
20090263484 | Tissue Engineering Devices and Methods for Luminal Organs - Tissue engineering devices and methods are provided for the reconstruction, repair, augmentation, or replacement of a luminal organ or tissue structure involving the use of a biodegradable polymer matrix conforming to a portion of a laminarly arranged luminal organ, the processing of autologous, allogeneic or xenogeneic tissue comprising multiple cell populations to obtain a minced tissue composition, the seeding of the matrix with the composition, and the implanting of the seeded polymer matrix into a patient. | 2009-10-22 |
20090263485 | Targeted hollow gold nanostructures and methods of use - Provided are novel nanostructures comprising hollow nanospheres and nanotubes for use as chemical sensors and molecular specific photothermal coupling agents. The nanostructures can be used in laser-induced phototherapy for treatment of cancer and other disorders. The nanostructures can also be used as a sensor that detects molecules. The nanostructures are of particular use in the fields of clinical diagnosis, clinical therapy, clinical treatment, and clinical evaluation of various diseases and disorders, manufacture of compositions for use in the treatment of various diseases and disorders, for use in molecular biology, structural biology, cell biology, molecular switches, molecular circuits, and molecular computational devices, and the manufacture thereof. The hollow gold nanospheres have a unique combination of spherical shape, small size, and strong, tunable, and narrow surface plasmon resonance absorption covering the entire visible to near IR region. | 2009-10-22 |
20090263486 | NANOPARTICLE-STABILIZED CAPSULE FORMULATION FOR TREATMENT OF INFLAMMATION - A formulation for the delivery of an anti-inflammatory agent to a subject is described. In one particular application of the invention, the formulation comprises oil-based or aqueous droplets comprising indomethacin (1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1-H-indole-3-acetic acid) or celecoxib (4-[5-(4-methylphenyl)-3-(trifluoromethyl) pyrazol-1-yl] benzenesulfonamide) stabilised by nanoparticles, particularly silica nanoparticles. | 2009-10-22 |
20090263487 | Bubble drink provided by bubbling engineering progress - A bubble drink as a health food, which is produced by imparting a catalytic function for gas escaping to an adsorptive fine food powder to allow the fine food powder to be dispersed in a colloidal solution reverse vessel, and reacting the dispersion with a gas-saturated solution to generate foam (a bubbling engineering process), whereby the food is converted into foam having a three-state composite structure of gas, liquid and solid states suitable to be ingested within a digestive system. | 2009-10-22 |
20090263488 | PRESSURISED METERED DOSE INHALERS CONTAINING SOLUTIONS OF BETA-2 AGONISTS - The present invention relates to a pharmaceutical formulation for use in the administration of 2(1H)-quinolinone derivatives long-acting β | 2009-10-22 |
20090263489 | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITIONS AND METHODS FOR REDUCING, PREVENTING OR TREATING PAIN AND INFLAMMATION - Effective treatments of acute pain and/or inflammation for extended periods of time are provided. Through the administration of an effective amount of sulfasalazine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days. | 2009-10-22 |
20090263490 | Microsphere beeswax for mammalian dietary fat mitigation - A device composed of a plurality of beeswax microspheres are contained within a digestible capsule intended for the alimentary tract of the mammal. A method in which the device is ingested orally into the digestive system. A method in which digestive enzymes remove the outside capsule and beeswax microspheres are then dispersed within the gastrointestinal tract. The beeswax microsphere is then able to come in contact with free fats, lipids, cholesterol and lipophillic toxins within the gut and absorb them into the lumen of the microsphere. The beeswax microsphere along with all the fats, lipids, cholesterol and lipophillic toxins contained within the microsphere transits through the remainder of the gut undigested and are eventually excreted from the rectum and bowel by fecal elimination. | 2009-10-22 |
20090263491 | Polylactide Nanoparticles - A drug targeting system for administering a pharmacologically active substance to the central nervous system of a mammal across the animal's blood brain barrier. The drug targeting system comprises nanoparticles made of poly(DL-lactide) and/or poly(DL-lactide-co-glycolide), a pharmacologically active substance which is absorbed to, adsorbed to, and/or incorporated into the nanoparticles, and either contains TPGS or comprises a pluronic 188 surfactant coating deposited on the drug-loaded nanoparticles. | 2009-10-22 |
20090263492 | Diagnostic Methods and Genetic Markers for Alzheimer Disease - Disclosed are methods for identifying individuals suffering from a CNS disorder (including Alzheimer's Disease, behavioral disorders, and the like) that could be treated with a CNS drug with greater therapeutic efficacy and lower side effects and the compounds useful for such treatment. Also disclosed are methods for predicting the efficacy of a drug candidate for the treatment of a CNS disorder. The technology is also applicable to drug discovery for use in animal models of neurodegenerative diseases. | 2009-10-22 |
20090263493 | Method for making synthetic slug slime and medical use of synthetic and or actual slug slime - The device hereof is most preferably the use of the slime coating of slugs or a synthetic copy of the slug slime, healing agents such as steroids antibiotics, growth hormones or pain killers can be mixed is with the slime before application to a burned or infected area. The slime thusly becomes a carrier for the medicines to the affected area as an antibiotic or anti fungal agent. Also, the same material can be used to protect and promote the healing of burns, due to its unique properties, of not only being hydroscopic and/or water absorbing, but also being non water soluble, as well as for its anti-infection properties. Another potentially helpful property of this material, is that it forms a protective skin-like membrane when spread over an area of skin and the observed condition was over burned skin. As an alternative to storing slug slime in the natural hydrated form, slug slime may be dehydrated at low temperatures under vacuum, in order to not harm its molecular structure or the organic chemical constituents which are part of it. After drying, the non hydrated slime may be ground into a powder form. From the powder form, it may be mixed with powdered healing agents, and or added to a solution, for reconstitution/re-hydrating with water, or other liquid in varying concentrations for conveniently spraying the solution or mixture on to burns or wounds in the form of a film. The reconstituted liquefied slime may also be sprayed on to a substrate for application as a sheet, or for applying to bandages for storage and later use. Powdered slug slime may be sprinkled directly on to burns or injuries, without first reconstituting it, allowing the substance to re-hydrate itself in place, on the injury or burn, taking water from the burn or wound. Additionally, there are ways to produce slug slime chemistry without the need to have slugs produce it. Also, cells within the slug which produce the slime may be genetically engineered to produce intended types of human cells instead of or within the slime they normally produce. Further, cells within the slug may be engineered to produce human stem cells, to become part of the slugs structure, or to be expressed as a part of or within the slime. If human cells such as skin cells can be manifested within the slime coating of slugs, the slime with the skin cells present may be applied directly to a burned skin surface. It is even possible, that the slime producing cells of the slug can be engineered to produce the same cells of the patient, by using genetic material from the patient. Slugs cells may be genetically engineered to produce human cells of many types, capable of transplanting to appropriate human body sites. | 2009-10-22 |
20090263494 | Manzanita - Applying the bark of the mariposa Manzanita shrub either mixed into a hot tea or added to mayonnaise and zinc for open sores will cure the herpes virus. | 2009-10-22 |
20090263495 | BACTERIOSTATIC OR BACTERIOCIDAL COMPOSITIONS AND METHODS - Particular aspects provide compositions and methods for treating or preventing bacterial infection or at least one symptom related to bacterial infection, and the like in a subject in need thereof by administering a therapeutic composition comprising at least one electrokinetically generated fluid (including gas-enriched electrokinetically generated fluids) as disclosed herein, the electrokinetically altered aqueous fluid suitable to alter cellular membrane structure or function sufficient to provide for modulation of intracellular signal transduction, wherein treating bacterial infection or at least one symptom related to bacterial infection is thereby afforded. In particular embodiments, the fluids are gas-enriched fluids or therapeutic compositions and methods, and include oxygen-enriched water optionally in combination with other therapeutic agents. Other embodiments include particular routes of administration or formulations for the gas-enriched therapeutic compositions. | 2009-10-22 |
20090263496 | METHOD FOR PRODUCING METAL PARTICLES, METAL PARTICLES PRODUCED THEREBY, AND THE USE THEREOF - Process for producing metal particle sols having a metal particle content of ≧1 g/l, comprising the steps of
| 2009-10-22 |
20090263497 | PRODUCTION METHOD FOR CALCIUM PHOSPHATE NANO-PARTICLES WITH HIGH PURITY AND THEIR USE - The present invention provides a continuous process for producing calcium phosphate nanoparticles in a network mixer or static mixer reactor, fed by a calcium solution, a phosphorous solution and an alkaline solution and, optionally, one solvent or dispersing agent. The proposed process enables the micromixing control, which is essential to form nanometric structures, but it is also a determining factor in the crystals purity, crystallinity and morphology. The reactants distribution scheme at the inlet of the reactor and along the reactor, performed continuously or varying in time, is also a crucial factor to programme the pH of the reactant media along the reactor The calcium phosphate nanoparticles suspension that exits the reactor can be submitted to further aging, ultra-sounds, separation, drying, sintering and milling processes. Some calcium phosphates are considered biomaterials, used as: food additives and nutritional supplements; bone graft for bone replacement, growth and repair; biocements and coating of metallic implant. Some of the most recent applications include their use in cosmetics, toothpaste and in esthetical treatments for diminishing wrinkles by stimulating conjunctive tissue formation. | 2009-10-22 |
20090263498 | Pharmaceutical preparations for treating inflammatory diseases - The present invention refers to a pharmaceutical preparation for treating inflammatory diseases and microbial infections comprising a pharmaceutically effective amount of ozone and at least one monomeric amino acid having an oxidation-sensitive side chain, or at least one ozonized monomeric amino acid having an oxidation-sensitive side chain. | 2009-10-22 |
20090263499 | AREA DECONTAMINATION VIA LOW-LEVEL CONCENTRATION OF GERMICIDAL AGENT - Provided is a method of decontaminating an area, and related device. The method comprises releasing a germicidal agent into the area from a germicidal source, controlling the germicidal agent concentration in the area to a predetermined concentration that does not exceed a Permissible Exposure Limit, and contacting microorganisms in the area with the germicidal agent to decontaminate the area. The device comprises a releasing mechanism configured to release a germicidal agent from a germicidal source at a predetermined concentration into the area such that the predetermined concentration of germicidal agent in the area does not exceed a Permissible Exposure Limit. | 2009-10-22 |
20090263500 | Composition and method for treating bedsores, cuts and burns - The invention provides a composition and method to prevent and treat bedsores rapidly, efficaciously and economically. The composition comprises a novel combination of herbal extracts that has surprisingly synergistic and highly efficacious effects for the acceleration of wound healing, and which also disinfects and relieves pain in dermal wounds. The composition can also be used for the rapid healing of dermal burns and dermal cuts. The composition is comprised of extracts of aloe vera, passion flower, goldenseal, and American ginseng, and optionally includes ionic silver and mimosa extract. The treatment method comprises administering a fluid and or gel form of the composition to the wounded skin and or wound cavity therein as a prophylactic or therapeutic dose, and may be delivered by means of a wound dressing. | 2009-10-22 |
20090263501 | ACTIVATED OXIDIZING VAPOR TREATMENT SYSTEM AND METHOD - An oxidizing liquid ( | 2009-10-22 |
20090263502 | Highly Dispersible Titanium Dioxide Powder - Provided is a means for controlling a plant disease or a pest insect by utilizing a highly dispersible titanium dioxide powder produced by a discharge treatment of a titanium dioxide powder. Titanium dioxide is a substance which is highly safe to living organisms and the environment. A plant disease or a pest insect can be controlled by utilizing the substance without adversely affecting the environment. | 2009-10-22 |
20090263503 | Compositions for Cleaning Contained Bodies of Water with Metal Hydrates - Compositions for cleaning, sanitizing and maintaining contained bodies of water such as swimming pools, wading pools, fountains, ornamental ponds, etc. The compositions include pre-determined percentages of hydrates of copper sulfate, zinc sulfate, and aluminum sulfate by weight. The composition uses hydrates of copper, zinc and aluminum sulfates instead of the anhydrous metal salts. The hydrate forms can be mined, transported, processed, mixed and packaged without climate controlled conditions necessary for anhydrous metal salts. Hydrates in the composition can gain additional water molecules or lose attached water molecules during manufacture, processing, transportation or use of the composition, without negatively affecting the physical format of the composition or reducing its effectiveness. The compositions reduce amounts of chlorine and an amount of labor associated with the cleaning, sanitization and maintenance of contained bodies of water. | 2009-10-22 |
20090263504 | METHODS AND COMPOSITIONS FOR PROMOTING ACTIVITY OF ANTI-CANCER THERAPIES - The present invention relates to a method of inhibiting growth of a cancerous cell. The method includes the step of exposing the cancerous cell to an anti-cancer therapy and an effective amount of a steroid saponin. | 2009-10-22 |
20090263505 | DIETARY THERAPEUTIC COMPOSITIONS FOR AMELIORATING DISEASE SYMPTOMS AND CONDITIONS ASSOCIATED WITH DIABETES - A daily dietary supplement for improving glucose metabolism, said dietary supplement comprising: an effective amount of a source of Alpha Lipoic Acid; an effective amount of a source of Salacia Oblonga; an effective amount of a source of Gymnema Sylvestre; an effective amount of a source of Chromium; an effective amount of a source of Cinnamon, an effective amount of a source of Banaba; and an effective amount of a source of Fenugreek. | 2009-10-22 |
20090263506 | CALCAREOUS ORGANISM GROWTH ACCELERATOR - The purpose of this invention is to provide compositions useful for promoting the growth of calcareous organisms present in a closed system aquatic habitat. Particularly, to composition capable of efficiently delivering calcium and carbonate to the calcareous organisms. Most particularly, to a composition effective for enhanced delivery of aragonite to a closed system aquatic habitat where it dissociates into bioavailable supplements, such as, calcium, strontium, magnesium, and carbonate ions, whereby enhanced growth of the calcareous organisms is achieved. | 2009-10-22 |
20090263507 | BIOLOGICAL MARKERS AND RESPONSE TO TREATMENT FOR PAIN, INFLAMMATION, NEURONAL OR VASCULAR INJURY AND METHODS OF USE - The invention provides methods and kits for treatment of pain, inflammation, neuronal or vascular injury and the use of biomarkers for the assessment of the biological activity or disease state. In one embodiment, the kit comprises a biomembrane sealing agent, such as PEG, a bioactive agent, such as a magnesium compound, and an assay for measuring a biomarker. The biomarker is measured pre-, mid- and post-treatment, and results of the measurements are compared to evaluate the treatment, treatment regimen and outcomes. | 2009-10-22 |
20090263508 | MICRONUTRIENT SUPPLEMENT WITH CALCIUM, VITAMIN D OR CALCIUM & VITAMIN D COMBINATION FOR PREMENSTRUAL SYNDROME, POSTPARTUM DEPRESSION, DEPRESSION AND PANIC ATTACKS - A bolus dose supplement, foodstuff, beverage and beverage concentrate with calcium and vitamin D for the treatment and prevention of PMS, panic attacks, and postpartum depression. The combination of adequate calcium and vitamin D is provided as a multi-vitamin and mineral supplement. The bolus dose is comprised of 2 main ingredients calcium and vitamin D at 1000-1500 mg of elemental calcium in the form of carbonate or citrate or gluconate or citrate maleate and 400-20,000 I.U. of parent vitamin D | 2009-10-22 |
20090263509 | ANTIBACTERIAL AGENT AND ANTIBACTERIAL COMPOSITION - The problems to be solved by the invention are to provide antibacterial agents originated from natural products that are safe for regular use with potent antibacterial activity, and antibacterial compositions containing said antibacterial agents. Antibacterial agents containing Eysenhardtia adenostylis extract or isoflavan compounds are a solution to the problem. Also antibacterial agents containing Eysenhardtia adenostylis extract or isoflavan compounds as active ingredients. The antibacterial agents can be applied to products such as cosmetics, including quasi-drugs, pharmaceuticals and foods. Further, antibacterial compositions containing these antibacterial agents, Eysenhardtia adenostylis extract or isoflavan compounds, and other compositions such as cosmetics, including quasi-drugs, pharmaceuticals and foods. | 2009-10-22 |
20090263510 | Process of making Hoodia plant extract with improved flavor - Processes of making extracts of | 2009-10-22 |
20090263511 | INSECTICIDAL COMPOSITION - The use of dill oil or a mixture of two or more components thereof as a potentiator for a pesticide, such as an insecticide and in particular a pyrethroid is described, together with compositions containing dill oil, and their use in agriculture and in veterinary applications. | 2009-10-22 |
20090263512 | COMPOSITION COMPRISING XANTHOCERAS SORBIFOLIA EXTRACTS, COMPOUNDS ISOLATED FROM SAME, METHODS FOR PREPARING SAME AND USES THEREOF - This invention provides compositions, methods and process of producing extracts from | 2009-10-22 |
20090263513 | COSMETIC SKIN LIGHTENING FORMULATION - The present invention features novel cosmetic skin care compositions for lightening hyperpigmentation. | 2009-10-22 |
20090263514 | Cold and flu tonic - A method and composition for reducing the symptoms of the common cold and flu in a human subject in need thereof, comprising the administration of an effective amount of an aqueous composition having all components dispersed as a dry powder concentrate or dissolved in a decoction therein comprising Black pepper, Cinnamon, Cumin, Ginger, Rose hip, Saffron, and Turmeric with Maple Syrup as a sweetener. | 2009-10-22 |
20090263515 | PEST REPELLENT COMPOSITIONS AND METHODS - The invention is directed to a topical insect repellent with extended duration of protection and that was obtained by combining natural and organic plant essential oil compounds. The new natural repellent exhibits the longevity and repellency that is comparable to or better than N,N-diethyl-m-toluamide (DEET), a synthetic compound employed in almost all commercial formulations, while at the same time is more acceptable than DEET, which has an unpleasant odor, imparts a greasy feel to the skin, and carries certain health concerns when used on children. The inventive insect repellent, formulated in a suitable carrier repels and incapacitates flying insects and other pests, such as mosquitoes and other biting flies or insects, thus demonstrating the utility of the novel insect repellent for protecting pets and livestock as well as humans. The invention provides an effective means to repel insects, without having deleterious effects on people, pets or the environment compared with prior insect repellant formulations. The repellant formulation disclosed herein may employ natural or organic active ingredient, e.g., plant essential oil compounds. | 2009-10-22 |
20090263516 | Plant Extract Composition and Their Use to Modulate Cellular Activity - Extracts from plant material, or semi-purified/purified molecules or compounds prepared from the extracts that demonstrate the ability to modulate one or more cellular activities are provided. The extracts are capable of slowing down, inhibiting or preventing cell migration, for example, the migration of endothelial cells or neoplastic cells and thus, the use of the extracts to slow down, inhibit or prevent abnormal cell migration in an animal is also provided. Methods of selecting and preparing the plant extracts and methods of screening the extracts to determine their ability to modulate one or more cellular activity are described. The purification or semi-purification of one or more molecules from the described extracts is also contemplated as well as the use of these molecules, alone or in combination with an extract, to slow down, inhibit or prevent abnormal cell migration in an animal. | 2009-10-22 |
20090263517 | METHOD FOR PRODUCING MARGOSA EXTRACT - The invention relates to a method for producing a margosa extract, an oil from cores and/or seeds of the neem tree being used and the oil being extracted using a carbon dioxide-containing extracting agent. The invention further relates to a margosa extract as is obtained using the method, its use as an agent for pest control and a composition for pest control which contains this extract. | 2009-10-22 |
20090263518 | Composition and Uses Thereof - A composition for topical application to the skin comprises a cocoa polyphenol extract in combination with an SUS-rich fat, wherein the cocoa polyphenol extract is present in an amount of less than 15% by weight based on the weight of the SUS-rich fat, and a cosmetically acceptable carrier. The composition and the extract that it contains may increase skin elasticity and thickness and/or have an anti-wrinkle effect, may cause the depigmentation of age spots, improve skin renewal and/or reduce skin dryness such as reducing discomfort of chapped hands. | 2009-10-22 |
20090263519 | COMPOSITION AND METHODS FOR INDUCING THE EXPRESSION OF HEAT SHOCK PROTEINS - A nutritional composition comprising at least an effective amount of geranylgeranylacetone or derivative of geranygeranylacetone and/or paeoniflorin or derivative of paeoniflorin and an effective amount of Schisandrin B, wherein the ingredients act substantially simultaneously, via differing mechanism, to enhance the expression of heat shock protein in cells, particularly heat shock protein 72 in skeletal muscle. A method of same is also provided. | 2009-10-22 |
20090263520 | NEMATICIDAL COMPOSITION - A nematicidal composition comprising (i) one or more essential oils selected from | 2009-10-22 |
20090263521 | COMPOSITION FOR THE TREATMENT OF CANCERS AND INHIBITION OF METASTASIS CONTAINING EXTRACTS OR FRACTIONS OF THE MAGNOLIA OBOVATA - The present invention relates to a composition containing the extracts of | 2009-10-22 |